In washed human platelets, rutin reduced aggregation induced by the PAR4 agonist AYPGKF after a 15-minute incubation at 30 or 45 μM. In a separate washout comparison within the same experiment, removal of 60 μM rutin restored aggregation. These findings support a reversible antiplatelet effect under the tested conditions. [1]
PDI reductase inhibition and limited thiol-isomerase selectivity panel
Biochemical assay · Purified recombinant human PDI; insulin-reduction assay; immobilized PDI in SPR [1]
Rutin inhibited PDI reductase activity and bound immobilized PDI. Other tested vascular thiol isomerases showed little inhibition under the reported conditions; this panel does not establish proteome-wide selectivity.
Literature-Reported Treatment Conditions
- Treatment concentration
- Assay-dependent concentration series; selectivity panel 0.3, 3 and 30 μM. SPR analyte 0–100 μM. IC50 is an endpoint, not a treatment dose.
- Exposure duration
- Insulin reaction monitored for 30 minutes; SPR analyte perfusion 2 minutes.
- Method
- Insulin assay with 0.8 μM PDI, 0.1 mM insulin and 0.75 mM DTT at 23°C; SPR uses immobilized PDI.
- Vehicle
- Insulin assay control buffer; SPR PBS with 0.005% P20 and 0.5% DMSO.
- Co-treatment
- None; DTT is assay reducing reagent.
- Reported limits
- Final solvent composition for the insulin assay and replicate n for Figure 1B are not specified at the adopted main-text locations.
Methods and source locations
Compound reported in the paper: Rutin (quercetin-3-rutinoside); Compound label in the paper: Quercetin-3-rutinoside
Evidence concerns the reported parent compound. No equivalence of hydrate states, salt conversion or Adooq lot performance is asserted.
Results identification/selectivity; Figures 1B–C and 3A–B; Methods insulin reduction assay and SPR
PDI-catalyzed insulin reduction: Insulin aggregation absorbance at 650 nm; nonlinear regression. Figure 1B reports mean ± SD. — Results identification; Figure 1B
Binding to immobilized PDI: Surface plasmon resonance with reference-surface subtraction; duplicate concentration sensorgrams. — Results identification; Figure 1C; Methods SPR
ERp5, ERp57, ERp72, thioredoxin and thioredoxin reductase comparison: Figure 3A: insulin reduction, mean and SD of 3 independent determinations. Figure 3B: thioredoxin/thioredoxin reductase system ±30 μM rutin. — Results selectivity; Figure 3A–B
Reversible inhibition of PAR4-stimulated human platelet aggregation
Cell-based study · Washed human platelets, 2 × 10^8 platelets/ml [1]
Rutin reduced PAR4 agonist-induced aggregation. Removing rutin by washing restored aggregation, with a vehicle-plus-wash control supporting reversibility. Antibody RL90 served as a PDI-inhibition comparator; this experiment alone does not establish exclusive PDI mediation.
Literature-Reported Treatment Conditions
- Treatment concentration
- 30 or 45 μM in the inhibition comparison; 60 μM in the washout experiment.
- Exposure duration
- 15-minute incubation before stimulation.
- Method
- Incubation at 37°C; stimulation with 50 μM PAR4 peptide AYPGKF; light transmission aggregometry.
- Vehicle
- PBS and 0.1% DMSO.
- Co-treatment
- No drug combination; AYPGKF is the activating stimulus, RL90 a separate comparator.
- Reported limits
- Donor count, biological replicate count and numerical effect estimates are not provided in Figure 4A–B/caption; no exact curve-derived values extracted.
Methods and source locations
Compound reported in the paper: Rutin (quercetin-3-rutinoside); Compound label in the paper: Quercetin-3-rutinoside
Evidence concerns the reported parent compound. No equivalence of hydrate states, salt conversion or Adooq lot performance is asserted.
Results platelet aggregation; Figure 4A–B; Methods platelet aggregation
AYPGKF-induced platelet aggregation: Light transmission aggregometry; anti-PDI RL90 comparator. — Figure 4A and caption; Results platelet aggregation
Aggregation following compound removal: Vehicle, rutin, vehicle followed by wash, and rutin followed by wash compared before agonist stimulation. — Figure 4B and caption; Results platelet aggregation
Rutin inhibition in a fluorogenic PDI reductase assay
Biochemical assay · Recombinant human wild-type PDI CC/CC, 45 nM; 10 μM bodipy-labeled L-cystine (BD-SS) [2]
Rutin produced concentration-dependent inhibition in a substrate system distinct from insulin. Isoquercetin was active, whereas quercetin showed only negligible inhibition at high concentration. The 4.6 μM estimate belongs to this assay and is not pooled with the earlier insulin-assay IC50.
Literature-Reported Treatment Conditions
- Treatment concentration
- Rutin concentration-response series; exact tested points not transcribed from logarithmic plot.
- Exposure duration
- Shared steady-state method: 10-minute compound–enzyme preincubation; rates assessed over 100–600 s.
- Method
- BD-SS fluorogenic reduction; shared steady-state buffer PBS pH 7.4, 2 mM EDTA and 10 μM DTT. Figure-specific enzyme concentration is 45 nM (not the general-method 30 nM).
- Vehicle
- Compounds dissolved in DMSO; final DMSO fraction not specified in the retrieved main manuscript.
- Co-treatment
- None; isoquercetin and quercetin are separate comparators.
- Reported limits
- No IC50 confidence interval or replicate n stated in Figure 4 caption. SI not retrieved. Final solvent fraction remains unknown.
Methods and source locations
Compound reported in the paper: Rutin (quercetin-3-rutinoside); Compound label in the paper: Rutin
Evidence concerns the reported parent compound. No equivalence of hydrate states, salt conversion or Adooq lot performance is asserted.
Figure 4A,E and caption; Methods Compounds and steady-state kinetics; Results glycosylation comparison
BD-SS reduction by PDI CC/CC: Fluorogenic reductase dose-response; 45 nM PDI and 10 μM BD-SS explicitly specified by Figure 4 caption. — Figure 4E and caption
Quercetin comparator inhibition: Separate aglycone comparator in the same assay; not a rutin result. — Figure 4E and caption